Navigation Links
Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board

AMSTERDAM, The Netherlands, April 2 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Dr. George Morstyn to be appointed to the Supervisory Board at its Annual General Meeting of shareholders on April 16, 2008. Dr. Morstyn (MB BS PhD FRACP), who retired as Senior Vice President of Development at Amgen, was a member of Amgen's executive committee and responsible for global preclinical and clinical development as well as regulatory affairs.

Dr. Morstyn also played an active role in representing Amgen to the financial community. Five new drugs and many label extensions were approved during his 11 year tenure. Dr. Morstyn graduated from Monash University, completed a Ph.D. with Professor Donald Metcalf at the Walter and Eliza Hall Institute and trained in medical oncology at the National Cancer Institute in the US. He was Head of the Clinical Program of the Ludwig Institute for Cancer Research in Melbourne for eight years. Dr. Morstyn was an early clinical investigator of several biological agents prior to joining Amgen, and performed seminal work on the development of G-CSF, which later became Neupogen, Amgen's second blockbuster drug. Dr. Morstyn is currently a board member of several Australian biotechnology companies.

Further to a plan of rotation, AMT aims to build a fully independent Supervisory Board in the course of 2008. Earlier this year, AMT announced the nominations of Alexander Ribbink, COO of TomTom, and Philippe van Holle, Head of Celgene Europe, to its Supervisory Board.

AMT's AGM is scheduled for April 16, 10:30 a.m., and will take place at the Rosarium, Amsterdam, The Netherlands.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
7. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
8. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
9. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
10. NIST team proves bridge from conventional to molecular electronics possible
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)...  Culprits beware, a University at Albany research ... is taking crime scene fingerprint identification to a ... -->   --> Photo ... --> Halámek and his team ... concept for identifying whether a culprit is male ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):